Literature DB >> 25626488

Therapeutic envelope vaccination in combination with antiretroviral therapy temporarily rescues SIV-specific CD4⁺ T-cell-dependent natural killer cell effector responses in chronically infected rhesus macaques.

Diego A Vargas-Inchaustegui1, Peng Xiao, Thorsten Demberg, Ranajit Pal, Marjorie Robert-Guroff.   

Abstract

Natural killer (NK) cells are essential components of the immune system, and due to their rapid response potential, can have a great impact during early anti-viral immune responses. We have previously shown that interleukin-2-dependent NK and CD4(+) T-cell co-operative immune responses exist in long-term simian immunodeficiency virus (SIV) -infected controlling macaques and can be rescued in SIV-infected non-controlling macaques by a short course of antiretroviral therapy (ART). Given that co-operative responses may play an important role in disease prevention and therapeutic treatment, in the present study we sought to determine if these responses can be enhanced in chronically SIV-infected macaques by vaccination with a single-dose of envelope protein given during ART. To this end, we treated 14 chronically SIV-infected macaques with ART for 11 weeks and gave 10 of these macaques a single intramuscular dose of SIV gp120 at week 9 of treatment. ART significantly decreased plasma and mucosal viral loads, increased the numbers of circulating CD4(+) T cells in all macaques, and increased T-cell-dependent envelope- and gag-specific interferon-γ and tumour necrosis factor-α production by circulatory CD56(+) NK cells. The therapeutic envelope immunization resulted in higher envelope-specific responses compared with those in macaques that received ART only. Functional T-cell responses restored by ART and therapeutic Env immunization were correlated with transiently reduced plasma viraemia levels following ART release. Collectively our results indicate that SIV-specific T-cell-dependent NK cell responses can be efficiently rescued by ART in chronically SIV-infected macaques and that therapeutic immunization may be beneficial in previously vaccinated individuals. Published 2015. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  T cells; antiretroviral therapy; envelope immunization; natural killer cells

Mesh:

Substances:

Year:  2015        PMID: 25626488      PMCID: PMC4427393          DOI: 10.1111/imm.12447

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  43 in total

1.  In vitro and in vivo responses to interleukin 12 are maintained until the late SIV infection stage but lost during AIDS.

Authors:  F Villinger; S Bucur; N F Chikkala; S S Brar; P Bostik; A E Mayne; J Adams; M E Lee; F J Novembre; M K Gately; A A Ansari; C D Hillyer
Journal:  AIDS Res Hum Retroviruses       Date:  2000-05-20       Impact factor: 2.205

2.  Antiretroviral therapy partly reverses the systemic and mucosal distribution of NK cell subsets that is altered by SIVmac₂₅₁ infection of macaques.

Authors:  Namal P M Liyanage; Shari N Gordon; Melvin N Doster; Poonam Pegu; Monica Vaccari; Nebiyu Shukur; Luca Schifanella; Cynthia A Pise-Masison; Danuta Lipinska; Kamil Grubczak; Marcin Moniuszko; Genoveffa Franchini
Journal:  Virology       Date:  2014-01-21       Impact factor: 3.616

3.  Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques.

Authors:  Diego A Vargas-Inchaustegui; Peng Xiao; Alison E Hogg; Thorsten Demberg; Katherine McKinnon; David Venzon; Egidio Brocca-Cofano; Janet Dipasquale; Eun M Lee; Lauren Hudacik; Ranajit Pal; Yongjun Sui; Jay A Berzofsky; Linda Liu; Solomon Langermann; Marjorie Robert-Guroff
Journal:  Virology       Date:  2013-10-09       Impact factor: 3.616

4.  Toll-like receptor-4 agonist in post-haemorrhage pneumonia: role of dendritic and natural killer cells.

Authors:  Antoine Roquilly; Alexis Broquet; Cedric Jacqueline; Laetitia Gautreau; Jean Pierre Segain; Pierre de Coppet; Jocelyne Caillon; Frédéric Altare; Regis Josien; Karim Asehnoune
Journal:  Eur Respir J       Date:  2013-01-11       Impact factor: 16.671

Review 5.  Immune interventions in HIV infection.

Authors:  Guislaine Carcelain; Brigitte Autran
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

6.  Decreased NK cell frequency and function is associated with increased risk of KIR3DL allele polymorphism in simian immunodeficiency virus-infected rhesus macaques with high viral loads.

Authors:  Pavel Bostik; Jaruda Kobkitjaroen; Weining Tang; Francois Villinger; Lara E Pereira; Dawn M Little; Susan T Stephenson; Mark Bouzyk; Aftab A Ansari
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

7.  CD4+ T-cell help enhances NK cell function following therapeutic HIV-1 vaccination.

Authors:  Stephanie Jost; Phillip John Tomezsko; Keith Rands; Ildiko Toth; Mathias Lichterfeld; Rajesh Tim Gandhi; Marcus Altfeld
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

8.  Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial.

Authors:  Poonam Pegu; Monica Vaccari; Shari Gordon; Brandon F Keele; Melvin Doster; Yongjun Guan; Guido Ferrari; Ranajit Pal; Maria Grazia Ferrari; Stephen Whitney; Lauren Hudacik; Erik Billings; Mangala Rao; David Montefiori; Georgia Tomaras; S Munir Alam; Claudio Fenizia; Jeffrey D Lifson; Donald Stablein; Jim Tartaglia; Nelson Michael; Jerome Kim; David Venzon; Genoveffa Franchini
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

9.  NK and CD4+ T cell cooperative immune responses correlate with control of disease in a macaque simian immunodeficiency virus infection model.

Authors:  Diego A Vargas-Inchaustegui; Peng Xiao; Iskra Tuero; L Jean Patterson; Marjorie Robert-Guroff
Journal:  J Immunol       Date:  2012-07-13       Impact factor: 5.422

10.  In vivo administration of a JAK3 inhibitor during acute SIV infection leads to significant increases in viral load during chronic infection.

Authors:  Yoshiaki Takahashi; Siddappa N Byrareddy; Christina Albrecht; Markus Brameier; Lutz Walter; Ann E Mayne; Paul Dunbar; Robert Russo; Dawn M Little; Tara Villinger; Ladawan Khowawisetsut; Kovit Pattanapanyasat; Francois Villinger; Aftab A Ansari
Journal:  PLoS Pathog       Date:  2014-03-06       Impact factor: 6.823

View more
  3 in total

1.  Two-Year Follow-Up of Macaques Developing Intermittent Control of the Human Immunodeficiency Virus Homolog Simian Immunodeficiency Virus SIVmac251 in the Chronic Phase of Infection.

Authors:  Iart Luca Shytaj; Gabrielle Nickel; Eric Arts; Nicholas Farrell; Mauro Biffoni; Ranajit Pal; Hye Kyung Chung; Celia LaBranche; David Montefiori; Diego Vargas-Inchaustegui; Marjorie Robert-Guroff; Mark G Lewis; Jonah B Sacha; Anna Teresa Palamara; Andrea Savarino
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

2.  Immune Checkpoint Blockade Restores HIV-Specific CD4 T Cell Help for NK Cells.

Authors:  Filippos Porichis; Meghan G Hart; Alexandra Massa; Holly L Everett; Antigoni Morou; Jonathan Richard; Nathalie Brassard; Maxime Veillette; Muska Hassan; Ngoc Le Ly; Jean-Pierre Routy; Gordon J Freeman; Mathieu Dubé; Andrés Finzi; Daniel E Kaufmann
Journal:  J Immunol       Date:  2018-06-22       Impact factor: 5.422

3.  A Pathogenic Role for Splenic B1 Cells in SIV Disease Progression in Rhesus Macaques.

Authors:  Gospel Enyindah-Asonye; Anthony Nwankwo; Christopher Hogge; Mohammad Arif Rahman; Sabrina Helmold Hait; Ruth Hunegnaw; Eun-Ju Ko; Tanya Hoang; David J Venzon; Marjorie Robert-Guroff
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.